{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:31:23Z","timestamp":1792099883917,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13045-019-0761-2","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T13:04:36Z","timestamp":1562677476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors"],"prefix":"10.1186","volume":"12","author":[{"given":"Weiping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Kundson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherine F.","family":"Elsawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo M.","family":"Sotomayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"issue":"1","key":"761_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood."},{"issue":"20","key":"761_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood."},{"issue":"28","key":"761_CR3","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452\u20139.","journal-title":"J Clin Oncol."},{"issue":"17","key":"761_CR4","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","volume":"114","author":"KJ Savage","year":"2009","unstructured":"Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533\u20137.","journal-title":"Blood."},{"issue":"4","key":"761_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med."},{"issue":"3","key":"761_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.leu.2404529","volume":"21","author":"P Bertrand","year":"2007","unstructured":"Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel MN, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia. 2007;21(3):515\u201323.","journal-title":"Leukemia."},{"issue":"11","key":"761_CR7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/cncr.28642","volume":"120","author":"JB Cohen","year":"2014","unstructured":"Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, et al. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120(11):1677\u201385.","journal-title":"Cancer."},{"issue":"11","key":"761_CR8","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","volume":"114","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273\u20139.","journal-title":"Blood."},{"issue":"1","key":"761_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/modpathol.3800500","volume":"19","author":"A Kanungo","year":"2006","unstructured":"Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24\/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25\u201333.","journal-title":"Mod Pathol."},{"issue":"10","key":"761_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3324\/haematol.11305","volume":"92","author":"S Le Gouill","year":"2007","unstructured":"Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC rearrangement. Haematologica. 2007;92(10):1335\u201342.","journal-title":"Haematologica."},{"issue":"3","key":"761_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","volume":"34","author":"M Snuderl","year":"2010","unstructured":"Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327\u201340.","journal-title":"Am J Surg Pathol."},{"issue":"7","key":"761_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3324\/haematol.2008.005355","volume":"94","author":"N Tomita","year":"2009","unstructured":"Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, et al. Clinicopathological features of lymphoma\/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94(7):935\u201343.","journal-title":"Haematologica."},{"issue":"2","key":"761_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.seminhematol.2015.01.009","volume":"52","author":"K Karube","year":"2015","unstructured":"Karube K, Campo E. MYC alterations in diffuse large B-cell lymphomas. Semin Hematol. 2015;52(2):97\u2013106.","journal-title":"Semin Hematol."},{"issue":"35","key":"761_CR14","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1200\/JCO.2013.54.9493","volume":"32","author":"TJ Molina","year":"2014","unstructured":"Molina TJ, Canioni D, Copie-Bergman C, Recher C, Briere J, Haioun C, et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte\/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014;32(35):3996\u20134003.","journal-title":"J Clin Oncol."},{"issue":"22","key":"761_CR15","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1182\/blood-2012-05-428466","volume":"120","author":"M Gupta","year":"2012","unstructured":"Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N, et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab\/R-CHOP. Blood. 2012;120(22):4400\u20136.","journal-title":"Blood."},{"issue":"24","key":"761_CR16","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","volume":"122","author":"G Ott","year":"2013","unstructured":"Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884\u201391.","journal-title":"Blood."},{"issue":"1","key":"761_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22\u201335.","journal-title":"Cell."},{"issue":"10","key":"761_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrc3984","volume":"15","author":"TR Kress","year":"2015","unstructured":"Kress TR, Sabo A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer. 2015;15(10):593\u2013607.","journal-title":"Nat Rev Cancer."},{"issue":"5","key":"761_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ejca.2005.11.022","volume":"42","author":"I Dimova","year":"2006","unstructured":"Dimova I, Raitcheva S, Dimitrov R, Doganov N, Toncheva D. Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours. Eur J Cancer. 2006;42(5):674\u20139.","journal-title":"Eur J Cancer."},{"issue":"6","key":"761_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/1947601910379132","volume":"1","author":"CM Koh","year":"2010","unstructured":"Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer. 2010;1(6):617\u201328.","journal-title":"Genes Cancer."},{"issue":"6","key":"761_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/1947601910378691","volume":"1","author":"J Xu","year":"2010","unstructured":"Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer. 2010;1(6):629\u201340.","journal-title":"Genes Cancer."},{"issue":"6","key":"761_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904\u201317.","journal-title":"Cell."},{"issue":"8","key":"761_CR23","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/j.celrep.2018.07.055","volume":"24","author":"E Derenzini","year":"2018","unstructured":"Derenzini E, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, et al. BET Inhibition-induced GSK3beta feedback enhances lymphoma vulnerability to PI3K inhibitors. Cell Rep. 2018;24(8):2155\u201366.","journal-title":"Cell Rep."},{"issue":"7327","key":"761_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature."},{"issue":"21","key":"761_CR25","doi-asserted-by":"publisher","first-page":"11625","DOI":"10.1021\/acs.chemrev.5b00205","volume":"115","author":"G Zhang","year":"2015","unstructured":"Zhang G, Smith SG, Zhou MM. Discovery of chemical inhibitors of human bromodomains. Chem Rev. 2015;115(21):11625\u201368.","journal-title":"Chem Rev."},{"issue":"2","key":"761_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0165-4608(03)00061-X","volume":"145","author":"SR Brockman","year":"2003","unstructured":"Brockman SR, Paternoster SF, Ketterling RP, Dewald GW. New highly sensitive fluorescence in situ hybridization method to detect PML\/RARA fusion in acute promyelocytic leukemia. Cancer Genet Cytogenet. 2003;145(2):144\u201351.","journal-title":"Cancer Genet Cytogenet."},{"issue":"14","key":"761_CR27","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","volume":"114","author":"M Gupta","year":"2009","unstructured":"Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009;114(14):2926\u201335.","journal-title":"Blood."},{"issue":"5","key":"761_CR28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","volume":"123","author":"A Chaidos","year":"2014","unstructured":"Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014;123(5):697\u2013705.","journal-title":"Blood."},{"issue":"6282","key":"761_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227\u201331.","journal-title":"Science."},{"issue":"9","key":"761_CR30","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","volume":"26","author":"JM Adams","year":"2007","unstructured":"Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324\u201337.","journal-title":"Oncogene."},{"issue":"18","key":"761_CR31","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.4161\/cc.25972","volume":"12","author":"F Braun","year":"2013","unstructured":"Braun F, de Carne Trecesson S, Bertin-Ciftci J, Juin P. Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival. Cell Cycle. 2013 Sep 15;12(18):2937\u201347.","journal-title":"Cell Cycle."},{"issue":"6","key":"761_CR32","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1073\/pnas.062036999","volume":"99","author":"T Berg","year":"2002","unstructured":"Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, et al. Small-molecule antagonists of Myc\/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A. 2002;99(6):3830\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"40","key":"761_CR33","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1038\/sj.onc.1206641","volume":"22","author":"X Yin","year":"2003","unstructured":"Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003;22(40):6151\u20139.","journal-title":"Oncogene."},{"issue":"4","key":"761_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","volume":"16","author":"CV Dang","year":"2006","unstructured":"Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253\u201364.","journal-title":"Semin Cancer Biol."},{"issue":"20","key":"761_CR35","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1101\/gad.1712408","volume":"22","author":"M Eilers","year":"2008","unstructured":"Eilers M, Eisenman RN. Myc's broad reach. Genes Dev. 2008;22(20):2755\u201366.","journal-title":"Genes Dev."},{"key":"761_CR36","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1038\/bcj.2013.24","volume":"3","author":"D Da Costa","year":"2013","unstructured":"Da Costa D, Agathanggelou A, Perry T, Weston V, Petermann E, Zlatanou A, et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013;3:e126.","journal-title":"Blood Cancer J."},{"issue":"26","key":"761_CR37","doi-asserted-by":"publisher","first-page":"E2721","DOI":"10.1073\/pnas.1406722111","volume":"111","author":"J Bhadury","year":"2014","unstructured":"Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A. 2014;111(26):E2721\u201330.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"761_CR38","doi-asserted-by":"crossref","unstructured":"Takimoto-Shimomura T, Tsukamoto T, Maegawa S, Fujibayashi Y, Matsumura-Kimoto Y, Mizuno Y, et al. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Invest New Drugs. 2019;37(2):210\u2013222.","DOI":"10.1007\/s10637-018-0623-8"},{"issue":"7370","key":"761_CR39","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524\u20138.","journal-title":"Nature."},{"issue":"5","key":"761_CR40","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","volume":"13","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014;13(5):1142\u201354.","journal-title":"Mol Cancer Ther."},{"issue":"6","key":"761_CR41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768\u201378.","journal-title":"Lancet Oncol."},{"issue":"4","key":"761_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322.","journal-title":"N Engl J Med."},{"issue":"14","key":"761_CR43","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41388-017-0111-1","volume":"37","author":"A Esteve-Arenys","year":"2018","unstructured":"Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1\/A1 in in vitro and in vivo models of MYC+\/BCL2+ double hit lymphoma. Oncogene. 2018;37(14):1830\u201344.","journal-title":"Oncogene."}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0761-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0761-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0761-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T23:19:03Z","timestamp":1594163943000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0761-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,9]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0761-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,9]]},"assertion":[{"value":"30 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}